TG Therapeutics, Inc.
TGTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001001316
In the last 90 days, TG Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 431 institutions reported holding it in 13F filings for Q2 2026, worth $6.10B in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in TG Therapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 356
- −18 vs. Q1 2025
- Shares held
- 101.6M
- +2.84M (+2.9%) vs. Q1 2025
- Total value
- $3.65B
- −$247.5M (−6.4%) vs. Q1 2025
- New holders
- 45
- 144 more added
- Sold out
- 63
- 105 more reduced
2 institutions that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TGTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 431 | $6.10B |
| Q1 2026 | 365 | $3.50B |
| Q4 2025 | 352 | $3.07B |
| Q3 2025 | 354 | $3.58B |
| Q2 2025 | 356 | $3.65B |
| Q1 2025 | 376 | $3.90B |
| Q4 2024 | 331 | $2.92B |
| Q3 2024 | 308 | $2.38B |
| Q2 2024 | 259 | $1.66B |
| Q1 2024 | 241 | $1.38B |
| Q4 2023 | 236 | $1.55B |
| Q3 2023 | 236 | $756.4M |
| Q2 2023 | 244 | $2.19B |
| Q1 2023 | 214 | $1.43B |
| Q4 2022 | 198 | $1.11B |
| Q3 2022 | 183 | $594.6M |
| Q2 2022 | 175 | $452.6M |
| Q1 2022 | 181 | $960.0M |
| Q4 2021 | 194 | $1.90B |
| Q3 2021 | 223 | $3.21B |
| Q2 2021 | 237 | $3.73B |
| Q1 2021 | 240 | $4.77B |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding TG Therapeutics, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Occudo Quantitative Strategies LP | 0 | $0 | 0.00% | −5,386−100.0% | Sold out |
| Buckingham Strategic Partners | 0 | $0 | 0.00% | −5,439−100.0% | Sold out |
| Pathstone Holdings, LLC | 0 | $0 | 0.00% | −5,365−100.0% | Sold out |
| Perbak Capital Partners LLP | 0 | $0 | 0.00% | −5,258−100.0% | Sold out |
| Highland Capital Management, LLC | 0 | $0 | 0.00% | −5,251−100.0% | Sold out |
| Advisors Asset Management, Inc. | 0 | $0 | 0.00% | −4,600−100.0% | Sold out |
| Cordant, Inc. | 0 | $0 | 0.00% | −2,590−100.0% | Sold out |
| Aster Capital Management (DIFC) Ltd | 0 | $0 | 0.00% | −3,243−100.0% | Sold out |
| Coldstream Capital Management Inc | 0 | $0 | 0.00% | −2,109−100.0% | Sold out |
| Boston Private Wealth LLC | 0 | $0 | 0.00% | −951−100.0% | Sold out |
| AdvisorNet Financial, Inc | 0 | $0 | 0.00% | −251−100.0% | Sold out |
| Darwin Advisors, LLC | 0 | $0 | 0.00% | −325−100.0% | Sold out |
| Harbour Investments, Inc. | 0 | $0 | 0.00% | −149−100.0% | Sold out |
| Stephens Consulting, LLC | 0 | $0 | 0.00% | −40−100.0% | Sold out |
| First Horizon Advisors, Inc. | 0 | $0 | 0.00% | −35−100.0% | Sold out |
| Wolff Wiese Magana LLC | 0 | $0 | 0.00% | −21−100.0% | Sold out |
| Frazier Financial Advisors, LLC | 0 | $0 | 0.00% | −20−100.0% | Sold out |
| CoreCap Advisors, LLC | 0 | $0 | 0.00% | −18−100.0% | Sold out |
| Continuum Advisory, LLC | 0 | $0 | 0.00% | −15−100.0% | Sold out |
| Redwood Investments, LLC | – | – | – | – | Not filed |
| Lindbrook Capital, LLC | – | – | – | – | Not filed |